Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.34 |
| ▸ | CHRNG | P07510 | 1/20 | 0.34 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CHRND | Q07001 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9778937 | 0.80 | HPGD (0.48) | MAOBMAOAOPRM1MAPT | |
| SCHEMBL12436884 | 0.73 | HSD17B10 (0.47) | ACHECYP3A4MAPT | |
| SCHEMBL9778865 | 0.71 | MMP2 (0.47) | MAOA | |
| SCHEMBL12436887 | 0.71 | OPRM1 (0.46) | MAOBMAOAACHECYP1A2POLB | |
| SCHEMBL19925337 | 0.71 | MAOB (0.35) | MAOBMAOAACHETDP1SLC6A2 | |
| SCHEMBL8064830 | 0.70 | BACE1 (0.42) | SLC6A2SLC6A3SLC6A4OPRM1 | |
| SCHEMBL9678382 | 0.69 | MAOB (0.33) | MAOBMAOAACHETDP1 | |
| SCHEMBL8297045 | 0.67 | ACHE (0.44) | MAOBMAOAACHETDP1SLC6A2 | |
| SCHEMBL4263043 | 0.65 | BACE1 (0.36) | — | |
| SCHEMBL11800829 | 0.63 | KMT2A (0.42) | MAOBMAOAACHETDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611120-A4 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2008-04-23 | — | — | EP | claimed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | claimed |
| EP-1611120-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Cortical Pty Ltd (AU) | 2006-01-04 | — | — | EP | claimed |
| WO-2004089927-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2004-10-21 | — | — | WO | claimed |
| US-7863313-B2 | Methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2011-01-04 | — | — | US | disclosed |
| US-7863313-B2 | Methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2011-01-04 | — | — | US | disclosed |
| US-7863313-B2 | Methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2011-01-04 | — | — | US | disclosed |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | CORTICAL PTY LTD (AU) | 2010-12-23 | — | — | US | disclosed |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | CORTICAL PTY LTD (AU) | 2010-12-23 | — | — | US | disclosed |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | CORTICAL PTY LTD (AU) | 2010-12-23 | — | — | US | disclosed |
| US-7446229-B2 | Bicyclic cannabinoids | UNIVERSITY OF CONNECTICUT (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446229-B2 | Bicyclic cannabinoids | UNIVERSITY OF CONNECTICUT (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1611120-A4 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2008-04-23 | — | — | EP | disclosed |
| US-20070135388-A1 | Novel Bicyclic Cannabinoids | UNIVERSITY OF CONNECTICUT | 2007-06-14 | — | — | US | disclosed |
| US-20070135388-A1 | Novel Bicyclic Cannabinoids | UNIVERSITY OF CONNECTICUT | 2007-06-14 | — | — | US | disclosed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | disclosed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | disclosed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | disclosed |
| EP-1611120-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Cortical Pty Ltd (AU) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089927-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | MIF, CCL2, CCL11 | MAOB 1574/4885MAOA 2413/4885ACHE 3239/4885 |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | MIF, CCL2, CCL11 | MAOB 1574/4885MAOA 2413/4885ACHE 3239/4885 |
| US-20070135388-A1 | Novel Bicyclic Cannabinoids | CNR2, CNR1, GPR18 | MAOB 1418/4885MAOA 2260/4885ACHE 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.